SCHEMBL14745203

SCHEMBL14745203

CCCC(=O)c1ccc2c(c1)cc(CO[Si](C)(C)C(C)(C)C)n2C

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B3 P37058 1/20 0.37
HPGD P15428 6/20 0.36
GAA P10253 2/20 0.36
NPC1 O15118 4/20 0.34
MEN1 O00255 3/20 0.34
KMT2A Q03164 3/20 0.34
KDM4E B2RXH2 1/20 0.34
ALOX15 P16050 1/20 0.34
CASP1 P29466 1/20 0.34
HSD17B10 Q99714 1/20 0.34
RAB9A P51151 4/20 0.33
MAPT P10636 3/20 0.33
ALDH1A1 P00352 2/20 0.33
NPSR1 Q6W5P4 1/20 0.33
PDE4D Q08499 3/20 0.32
PDE4A P27815 2/20 0.32
PDE4B Q07343 2/20 0.32
PDE4C Q08493 2/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14745543 0.91 SIGMAR1 (0.34) HPGDNPC1RAB9AMAPTSMN1; SMN2
SCHEMBL14745877 0.89 HPGD (0.35) HSD17B3HPGDGAANPC1MEN1
SCHEMBL14745668 0.86 HCAR3 (0.40) HPGDNPC1KDM4EHSD17B10RAB9A
SCHEMBL14744974 0.84
SCHEMBL14744975 0.84
SCHEMBL14744790 0.82 IDO1 (0.39) HPGDNPC1KMT2AKDM4EALOX15
SCHEMBL14744689 0.81 MLYCD (0.34) HPGDNPC1KDM4EHSD17B10RAB9A
SCHEMBL16440987 0.79 HSD17B3 (0.44) HSD17B3HPGDGAANPC1MEN1
SCHEMBL14744861 0.78 NPC1 (0.37) HSD17B3HPGDGAANPC1MEN1
SCHEMBL16440999 0.78 HSD17B3 (0.42) HSD17B3HPGDGAANPC1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9409905-B2 Antibacterial compounds and methods for use PTC THERAPEUTICS, INC. (US) 2016-08-09 US disclosed
US-20150038437-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC THERAPEUTICS, INC. (US) 2015-02-05 US disclosed
EP-2750504-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC Therapeutics, Inc. (US) 2014-07-09 EP disclosed
WO-2013033258-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC THERAPEUTICS, INC. (US) 2013-03-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150038437-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE MRPL21, SLC11A2, CLPP HSD17B3 3833/4885HPGD 1279/4885GAA 91/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.